A preview of Neurocrine’s muscarinic drug readout

This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

Welcome back! I’ve been working from home almost this entire summer because of construction on the Red Line. I hate the MBTA. Boston readers know what I mean.

advertisement

This week: “Muscarinics” are hot and Neurocrine Biosciences is the next biotech with a big study readout. I preview. Also, a few more words on the Cassava Sciences’ soap opera.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe